Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.

Cigna Healthcare, the health benefits division of the Cigna Group, has released a set of digital tools aimed at improving the ...

By Amina Niasse (Reuters) -Hims & Hers Health is betting that the cash-pay market for weight-loss drugs will drive up customer demand although some analysts see a need for the online website to adjust ...

Hims & Hers Health is betting that the cash-pay market for weight-loss drugs will drive up customer demand although some analysts see a need for the online website to adjust to changing competition in ...

The percentage of adults prescribed a GLP-1 drug like Wegovy or Zepbound jumped almost sevenfold over the past five years, according to a new report. ... Novo and Lilly partnered with Cigna’s health ...

Cigna now offers employers $200 Wegovy, Zepbound copay option. The new weight-loss option will cut what the plan sponsors pay as well as what the patients pay, Cigna’s PBM Evernorth says.

Hims & Hers stock took a nosedive after Cigna’s Evernorth division announced a $200 monthly cap on popular weight-loss drugs Wegovy and Zepbound. This move undercuts the cash-pay market where these ...

The Cigna Group (NYSE:CI)’s Evernorth division has announced a new deal with Novo Nordisk and Eli Lilly that will limit insured customers’ monthly out-of-pocket expenses for weight-loss drugs ...

Cigna will cap out-of-pocket costs at $200 per month for patients using the weight-loss drugs Wegovy and Zepbound through an add-on to its pharmacy benefit management plans, the company announced ...

Investing.com -- Cigna’s Evernorth has introduced a new pharmacy benefit that caps out-of-pocket costs for GLP-1 weight loss medications at $200 per month, in a move analysts say is more ...

The endorsement follows a recent announcement by Cigna/Evernorth, which introduced a new benefit option that limits patient copays to $200 per month for Lilly’s Zepbound and Novo’s Wegovy.